A subgroup analysis of a randomized trial showed that patients with previously treated metastatic renal cell carcinoma had significant improvement in progression-free survival when they received everolimus.
Motzer RJ, Escudier B, Oudard S, et al.
Advertisement
Articles by Motzer RJ, Escudier B, Oudard S, et al.
Advertisement
Latest Updated Articles
Everolimus Improves Progression-Free Survival in Patients with Previously Treated Metastatic RCCPublished: March 22nd 2011 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
2
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
3
FDA Underscores Risks Associated With DPD Deficiency and Capecitabine/5-FU Use in Cancer Care
4
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
5